Phenotypic and molecular characterization of Neisseria gonorrhoeae isolates from Slovenia, 2006-12: Rise and fall of the multidrug-resistant NG-MAST genogroup 1407 clone?

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 6, 2014, Pages 1517-1525

  Jeverica, Samo ^a   Golparian, Daniel ^b   Matičič, Mojca ^c   Potočnik, Marko ^c   Mlakar, Boštjan ^d   Unemo, Magnus ^b  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^d Surgical Centre Zdrav Splet   (Slovenia)

Author keywords

Antimicrobial resistance; Cefixime; Ceftriaxone; ESCs; Extended spectrum cephalosporins; Gonorrhoea

Indexed keywords

AZITHROMYCIN; BACTERIAL PROTEIN; CEFIXIME; CEFTRIAXONE; CIPROFLOXACIN; GENTAMICIN; MTRR PROTEIN; PENA PROTEIN; PENB PROTEIN; PENICILLIN DERIVATIVE; SPECTINOMYCIN; TETRACYCLINE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ALLELE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENETICS; BACTERIAL STRAIN; BACTERIUM ISOLATE; CLONE; DISEASE TRANSMISSION; FEMALE; GENE DELETION; GENE SEQUENCE; GONORRHEA; HETEROSEXUALITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEN WHO HAVE SEX WITH MEN; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR EPIDEMIOLOGY; MULTIDRUG RESISTANCE; NEISSERIA GONORRHOEAE; NEISSERIA GONORRHOEAE MULTIANTIGEN SEQUENCE TYPING; PHENOTYPE; PROMOTER REGION; SLOVENIA; AMINO ACID SUBSTITUTION; BACTERIAL GENE; DRUG EFFECTS; EPIDEMIOLOGY; GENETICS; GENOTYPE; HISTORY; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MULTILOCUS SEQUENCE TYPING; MUTATION; SEASON; YOUNG ADULT;

ADOLESCENT; ADULT; ALLELES; AMINO ACID SUBSTITUTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; GENES, BACTERIAL; GENOTYPE; GONORRHEA; HISTORY, 21ST CENTURY; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MULTILOCUS SEQUENCE TYPING; MUTATION; NEISSERIA GONORRHOEAE; PHENOTYPE; SEASONS; SLOVENIA; YOUNG ADULT;

EID: 84903521692     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku026     Document Type: Article

References (49)

1. WHO. Global Incidence and Prevalence of Selected Curable Sexually Transmitted Infections-2008. http://www.who.int/reproductivehealth/publications/rtis/2008_STI_estimates.pdf (9 January 2014, date last accessed).
2. European Centre for Disease Prevention and Control. Sexually Transmitted Infections in Europe 2011. http://www.ecdc.europa.eu/en/publications/publications/sexually-transmitted-infections-europe-2011. pdf (9 January 2014, date last accessed).
3. Potočnik M, Barač M. The current situation concerning syphilis and gonorrhoea in Slovenia. Acta Dermatovenerolog Alp Panon Adriat 1995; 4: 141-4.
4. Tapsall JW, Ndowa F, Lewis DA et al. Meeting the public health challenge of multidrug-and extensively drug-resistant Neisseria gonorrhoeae. Expert Rev Anti Infect Ther 2009; 7: 821-34.
5. Unemo M, Nicholas RA. Emergence of multi-drug resistant, extensively drug-resistant and untreatable gonorrhea. Future Microbiol 2012; 7: 1401-22.
6. Deguchi T, Yasuda M, Yokoi S et al. Treatment of uncomplicated gonococcal urethritis by double-dosing of 200 mg cefixime at a 6-h interval. J Infect Chemother 2003; 9: 35-9.
7. Yokoi S, Deguchi T, Ozawa T et al. Threat to cefixime treatment for gonorrhea. Emerg Infect Dis 2007; 13: 1275-7.
8. Ison CA, Hussey J, Sankar KN et al. Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010. Euro Surveill 2011; 16: pii=19833.
9. Unemo M, Golparian D, Nicholas R et al. High-level cefixime-and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother 2012; 56: 1273-80.
10. Unemo M, Golparian D, Stary A et al. First Neisseria gonorrhoeae strain with resistance to cefixime causing gonorrhoea treatment failure in Austria, 2011. Euro Surveill 2011; 16: pii=19998.
11. Unemo M, Golparian D, Syversen G et al. Two cases of verified clinical failures using internationally recommended first-line cefixime for gonorrhoea treatment, Norway, 2010. Euro Surveill 2010; 15: pii=19721.
12. Lewis DA, Sriruttan C, Müller EE et al. Phenotypic and genetic characterization of the first two cases of extended-spectrumcephalosporin-resistant Neisseria gonorrhoeae infection in South Africa and association with cefixime treatment failure. J Antimicrob Chemother 2013; 68: 1267-70.
13. Allen VG, Mitterni L, Seah C et al. Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada. JAMA 2013; 309: 163-70.
14. Unemo M, Golparian D, Potočnik M et al. Treatment failure of pharyngeal gonorrhoea with internationally recommended first-line ceftriaxone verified in Slovenia, September 2011. Euro Surveill 2012; 17: pii=20200.
15. Unemo M, Golparian D, Hestner A. Ceftriaxone treatment failure of pharyngeal gonorrhoea verified by international recommendations, Sweden, July 2010. Euro Surveill 2011; 16: pii=19792.
16. Tapsall J, Read P, Carmody C et al. Two cases of failed ceftriaxone treatment in pharyngeal gonorrhoea verified by molecular microbiological methods. J Med Microbiol 2009; 58: 683-7.
17. Chen YM, Stevens K, Tideman R et al. Failure of ceftriaxone 500 mg to eradicate pharyngeal gonorrhoea, Australia. J Antimicrob Chemother 2013; 68: 1445-7.
18. Ohnishi M, Golparian D, Shimuta K et al. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea? Detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother 2011; 55: 3538-45.
19. Read PJ, Limnios EA, McNulty A et al. One confirmed and one suspected case of pharyngeal gonorrhoea treatment failure following 500 mg ceftriaxone in Sydney, Australia. Sex Health 2013; 10: 460-2.
20. Camara J, Serra J, Ayats J et al. Molecular characterization of two high-level ceftriaxone-resistant Neisseria gonorrhoeae isolates detected in Catalonia, Spain. J Antimicrob Chemother 2012; 67: 1858-60.
21. WHO. Global Action Plan to Control the Spread and Impact of Antimicrobial Resistance in Neisseria gonorrhoeae. 2012. http://www. who.int/reproductivehealth/publications/rtis/9789241503501 (9 January 2014, date last accessed).
22. European Centre for Disease Prevention and Control. Response Plan to Control and Manage the Threat of Multidrug-Resistant Gonorrhoea in Europe. 2012. http://www.ecdc.europa.eu/en/publications/Publications/1206-ECDC-MDR-gonorrhoea-response-plan.pdf (9 January 2014, date last accessed).
23. CDC. Cephalosporin-resistant Neisseria gonorrhoeae Public Health Response Plan. 2012. http://www.cdc.gov/std/treatment/ceph-rresponseplanjuly30-2012.pdf (9 January 2014, date last accessed).
24. Ameyama S, Onodera S, Takahata M et al. Mosaic-like structure of penicillin-binding protein 2 gene (penA) in clinical isolates of Neisseria gonorrhoeae with reduced susceptibility to cefixime. Antimicrob Agents Chemother 2002; 46: 3744-9.
25. Lee SG, Lee H, Jeong SH et al. Various penA mutations together with mtrR, porB and ponA mutations in Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime or ceftriaxone. J Antimicrob Chemother 2010; 65: 669-75.
26. Osaka K, Takakura T, Narukawa K et al. Analysis of amino acid sequences of penicillin-binding protein 2 in clinical isolates of Neisseria gonorrhoeae with reduced susceptibility to cefixime and ceftriaxone. J Infect Chemother 2008; 14: 195-203.
27. Takahata S, Senju N, Osaki Y et al. Amino acid substitutions in mosaic penicillin-binding protein 2 associated with reduced susceptibility to cefixime in clinical isolates of Neisseria gonorrhoeae. Antimicrob Agents Chemother 2006; 50: 3638-45.
28. Tomberg J, Unemo M, Davies C et al. Molecular and structural analysis of mosaic variants of penicillin-binding protein 2 conferring decreased susceptibility to expanded-spectrum cephalosporins in Neisseria gonorrhoeae: role of epistatic mutations. Biochemistry 2010; 49: 8062-70.
29. Zhao S, Duncan M, Tomberg J et al. Genetics of chromosomally mediated intermediate resistance to ceftriaxone and cefixime in Neisseria gonorrhoeae. Antimicrob Agents Chemother 2009; 53: 3744-51.
30. Folster JP, Johnson PJ, Jackson L et al. MtrR modulates rpoH expression and levels of antimicrobial resistance in Neisseria gonorrhoeae. J Bacteriol 2009; 19: 287-97.
31. Ohneck EA, Zalucki YM, Johnson PJ et al. A novel mechanism of high-level, broad-spectrum antibiotic resistance caused by a single base pair change in Neisseria gonorrhoeae. mBio 2011; 2: pii=e00187-11.
32. Olesky M, Hobbs M, Nicholas RA. Identification and analysis of amino acid mutations in porin IB that mediate intermediate-level resistance to penicillin and tetracycline in Neisseria gonorrhoeae. Antimicrob Agents Chemother 2002; 46: 2811-20.
33. Olesky M, Zhao S, Rosenberg RL et al. Porin-mediated antibiotic resistance in Neisseria gonorrhoeae: ion, solute, and antibiotic permeation through PIB proteins with penB mutations. J Bacteriol 2006; 188: 2300-8.
34. Unemo M, Dillon JA. Review and international recommendation of methods for typing Neisseria gonorrhoeae isolates and their implications for improved knowledge of gonococcal epidemiology, treatment, and biology. Clin Microbiol Rev 2011; 24: 447-58.
35. Klavs I, Kustec T, Kastelic Z. Sexually Transmitted Diseases in Slovenia, Annual Report 2011. Ljubljana: National Institute for Public Health of Slovenia, 2012. www.ivz.si/hiv_spo?pi=5&_5_Filename=5502.pdf&_5_ MediaId=5502&_5_AutoResize=false&l=107-5.3 (9 January 2014, date last accessed).
36. Unemo M, Fasth O, Fredlund H et al. Phenotypic and genetic characterization of the 2008 WHO Neisseria gonorrhoeae reference strain panel intended for global quality assurance and quality control of gonococcal antimicrobial resistance surveillance for public health purposes. J Antimicrob Chemother 2009; 63: 1142-51.
37. EUCAST. Breakpoint Tables for Interpretation of MICs and Zone Diameters V3.1. 2013. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/Breakpoint_table_v_3.1.pdf (9 January 2014, date last accessed).
38. Ison CA, Town K, Obi C et al. Decreased susceptibility to cephalosporins among gonococci: data from the Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) in England and Wales, 2007-2011. Lancet Infect Dis 2013; 13: 762-8.
39. Chisholm S, Unemo M, Quaye N et al. Molecular epidemiological typing within the European Gonococcal Antimicrobial Resistance Surveillance Programme reveals predominance of a multidrug-resistant clone. Euro Surveill 2013; 18: pii=20358.
40. Unemo M, Olcén P, Fredlund H et al. Real-time PCR and subsequent pyrosequencing for screening of penA mosaic alleles and prediction of reduced susceptibility to expanded-spectrum cephalosporins in Neisseria gonorrhoeae. APMIS 2008; 116: 1004-8.
41. Lindberg R, Fredlund H, Nicholas R et al. Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porB1b, and ponA. Antimicrob Agents Chemother 2007; 51: 2117-22.
42. Bignell C, Fitzgerald M, Guideline Development Group. UK national guideline for the management of gonorrhoea in adults, 2011. Int J STD AIDS 2011; 22: 541-7.
43. CDC. Update to CDC's sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly Rep 2012; 61: 590-4.
44. Bignell C, Unemo M. 2012 European guideline on the diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS 2013; 24: 85-92.
45. Tanaka M, Koga Y, Nakayama H et al. Antibiotic-resistant phenotypes and genotypes of Neisseria gonorrhoeae isolates in Japan: identification of strain clusters with multidrug-resistant phenotypes. Sex Transm Dis 2011; 38: 871-5.
46. Martin I, Sawatzky P, Allen V et al. Emergence and characterization of Neisseria gonorrhoeae isolates with decreased susceptibilities to ceftriaxone and cefixime in Canada: 2001-2010. Sex Transm Dis 2012; 39: 316-23.
47. Pandori M, Barry PM, Wu A et al. Mosaic penicillin-binding protein 2 in Neisseria gonorrhoeae isolates collected in 2008 in San Francisco, California. Antimicrob Agents Chemother 2009; 53: 4032-4.
48. Tapsall JW, Ray S, Limnios A. Characteristics and population dynamics of mosaic penA allele-containing Neisseria gonorrhoeae isolates collected in Sydney, Australia, in 2007-2008. Antimicrob Agents Chemother 2010; 54: 554-6.
49. European Centre for Disease Prevention and Control. Gonococcal Antimicrobial Susceptibility Surveillance in Europe 2011. http://www. ecdc.europa.eu/en/publications/publications/gonococcal-antimicrobialsusceptibility-surveillance-27-mar-2013.pdf (9 January 2014, date last accessed).